Study details
Enrolling now
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT IDNCT07392242ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
60+
Locations
7 sites in NJ, NY
About this study
This Phase 2 study is testing Azacitidine in people with leukemia. The primary outcome being measured is Event free survival.
Based on ClinicalTrials.gov records.
PhasePhase 2
DrugAzacitidine
Routeinjection
Primary goalEvent free survival
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
azacitidine, ivosidenib, venetoclax
Drug routes
injection, subcutaneous, oral (Oral Tablet), oral
Endpoints
Primary: Event free survival
Body systems
Oncology